Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors.Gusach, A., Luginina, A., Marin, E., Brouillette, R.L., Besserer-Offroy, E., Longpre, J.M., Ishchenko, A., Popov, P., Patel, N., Fujimoto, T., Maruyama, T., Stauch, B., Ergasheva, M., Romanovskaia, D., Stepko, A., Kovalev, K., Shevtsov, M., Gordeliy, V., Han, G.W., Katritch, V., Borshchevskiy, V., Sarret, P., Mishin, A., Cherezov, V.
(2019) Nat Commun 10: 5573-5573
- PubMed: 31811124
- DOI: https://doi.org/10.1038/s41467-019-13348-2
- Primary Citation of Related Structures:
6RZ6, 6RZ7, 6RZ8, 6RZ9
- PubMed Abstract:
Cysteinyl leukotriene G protein-coupled receptors CysLT 1 and CysLT 2 regulate pro-inflammatory responses associated with allergic disorders. While selective inhibition of CysLT 1 R has been used for treating asthma and associated diseases for over two decades, CysLT 2 R has recently started to emerge as a potential drug target against atopic asthma, brain injury and central nervous system disorders, as well as several types of cancer. Here, we describe four crystal structures of CysLT 2 R in complex with three dual CysLT 1 R/CysLT 2 R antagonists. The reported structures together with the results of comprehensive mutagenesis and computer modeling studies shed light on molecular determinants of CysLTR ligand selectivity and specific effects of disease-related single nucleotide variants.
Institut de Biologie Structurale Jean-Pierre Ebel, Université Grenoble Alpes-Commissariat à l'Energie Atomique et aux Energies Alternatives-CNRS, Grenoble, France.